SCHEMBL14095983

SCHEMBL14095983

COc1cc2c(Nc3ccc(Cl)cc3F)ncnc2cc1OCCC1CCN(C)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 18/20 1.00
FLT1 P17948 18/20 1.00
KDR P35968 18/20 1.00
EGFR P00533 14/20 1.00
FLT4 P35916 14/20 1.00
PDGFRB P09619 2/20 0.70
TEK Q02763 2/20 0.70
EPHA2 P29317 2/20 0.70
EPHB4 P54760 2/20 0.70
EPHB2 P29323 2/20 0.70
BMPR1B O00238 1/20 0.70
PLK4 O00444 1/20 0.70
CIT O14578 1/20 0.70
GAK O14976 1/20 0.70
EPHB6 O15197 1/20 0.70
RIPK2 O43353 1/20 0.70
ROCK2 O75116 1/20 0.70
STK10 O94804 1/20 0.70
MAP4K4 O95819 1/20 0.70
ABL1 P00519 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2137353 0.92 EGFR (0.98) FGFR1FLT1KDREGFRFLT4
SCHEMBL27218222 0.91 EGFR (1.00) FGFR1FLT1KDREGFRFLT4
Hydrochloric Acid SCHEMBL2140851 0.91 EGFR (1.00) FGFR1FLT1KDREGFRFLT4
SCHEMBL5433644 0.89 FLT1 (0.83) FGFR1FLT1KDREGFRFLT4
SCHEMBL7864669 0.87 KDR (1.00) FGFR1FLT1KDREGFRFLT4
SCHEMBL1885485 0.87 FGFR1 (0.77) FGFR1FLT1KDREGFRFLT4
SCHEMBL5428945 0.87 FLT1 (0.77) FGFR1FLT1KDREGFRFLT4
SCHEMBL7867152 0.86 KDR (0.98) FGFR1FLT1KDREGFRFLT4
SCHEMBL1467367 0.86 FGFR1 (1.00) FGFR1FLT1KDREGFRFLT4
SCHEMBL3136293 0.86 EGFR (0.85) FGFR1FLT1KDREGFRFLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240156825-A1 USE OF SELECTIVE VEGFR2 AND FGFR1 INHIBITORS FOUNTAIN THERAPEUTICS INC (US) 2024-05-16 US disclosed
US-20080199480-A1 Methods for Identifying Risk of Type II Diabetes and Treatments Thereof SEQUENOM, INC. (US) 2008-08-21 US disclosed
US-20080199480-A1 Methods for Identifying Risk of Type II Diabetes and Treatments Thereof SEQUENOM, INC. (US) 2008-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080199480-A1 Methods for Identifying Risk of Type II Diabetes and Treatments Thereof SLC5A2, GCKR, IAPP FGFR1 3131/4885FLT1 3662/4885KDR 2859/4885
US-20240156825-A1 USE OF SELECTIVE VEGFR2 AND FGFR1 INHIBITORS FGFR1, FRS2, FGFR2 FGFR1 1/4885FLT1 4/4885KDR 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.